Furthermore, the combination of AT-II and AT-III with FDA-approved drugs enhanced sensitivity in XPC-KD-resistant renal cell carcinoma (RCC) cells, overcoming XPC deficiency-mediated resistance [74]. Here, XPC is linked to renal cell carcinoma.